News
News and events as they happenAZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF EPRONTIA™ (topiramate) oral solution
The first and only FDA-approved ready-to-use liquid topiramate WOBURN, MA, November 8, 2021-Azurity Pharmaceuticals, Inc. a private specialty pharmaceutical company focused on developing innovative products to meet the unique needs of patients with underserved...
Azurity Pharmaceuticals Completes Acquisition of Arbor Pharmaceuticals
WOBURN, MA & ATLANTA, GA (September 20, 2021) – Azurity Pharmaceuticals, Inc. (“Azurity”) is pleased to announce the closing of its acquisition of Arbor Pharmaceuticals, Inc. (“Arbor”), as previously announced on August 24, 2021. The acquisition creates a leading...
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of One Lot of Firvanq® (vancomycin hydrochloride for oral solution), Vancomycin 50 mg/mL Kit, Due to a Mix-Up of the Diluent Included in the Kit
FOR IMMEDIATE RELEASE – September 7, 2021 – Wilmington, MA, Azurity Pharmaceuticals, Inc. (“Azurity”) is voluntarily recalling one lot of Firvanq® (vancomycin hydrochloride for oral solution), Vancomycin 50 mg/mL Kit (“Firvanq®”) to the consumer level, as some products in the affected lot have been found to incorrectly contain a First Omeprazole (FIRST-PPI) diluent instead of the Firvanq diluent bottle.